NCT05186415View on ClinicalTrials.gov

Contrast Enhanced Three Dimensional Echocardiographic Quantification of Right Ventricular Volumes in Repaired Congenital Heart Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2024

Conditions
Tetralogy of FallotPulmonary Insufficiency
Interventions
DRUG

Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]

The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.

Trial Locations (1)

19803

Nemours Childrens Hospital, Wilmington

All Listed Sponsors
collaborator

Thomas Jefferson University

OTHER

lead

Nemours Children's Clinic

OTHER